Generalized Pustular Psoriasis in a 6‐week‐old Infant

Chao, Pei-Hsin; Cheng, Yu‐Wen; Chung, Mei‐Ing

doi:10.1111/j.1525-1470.2009.00918.x

Cited by 31 publications

(25 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The information was available for all interventions within 3 months of therapy initiation, between 3 and 6 months for nine (35%) interventions, and after 6 months for six (23%) interventions. The most commonly used therapies to control pediatric GPP were acitretin, CyA, and MTX . All patients received one of these three medications at some point during the course of their disease, although in some cases information was mentioned as “previously used therapies” or a detailed description was not provided.…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Systemic Medications for Pustular Psoriasis in Pediatrics

Rios

Pope

Lara‐Corrales

2014

Pediatric Dermatology

View full text Add to dashboard Cite

There is lack of information and evidence-based studies on the treatment of pediatric pustular psoriasis. Previous reports have emphasized the limitations of the existing data and encouraged the exploration of therapy optimization through more structured research. The objective of the current study was to perform a systematic review of systemic interventions for pediatric pustular psoriasis with an emphasis on clinical response and treatment outcomes. A systematic literature search was conducted using the PubMed and Embase databases from 1982 to 2012. Of 632 references identified, 14 met our inclusion criteria and were included in the analysis. A cohort of eight patients from the Hospital for Sick Children, Toronto, Canada, was also included. Information was limited to systemic treatments in children. Only English- and Spanish-language articles were included. Information was gathered from 24 patients, 22 of whom (92%) presented with generalized pustular psoriasis and 2 (8%) with acral distribution. The mean age at presentation was 6.3 ± 4.9 years. More than one intervention was required in 12 (50%) cases. The most common therapies used for generalized pustular psoriasis were acitretin, cyclosporine, and methotrexate. We identified that there is lack of information regarding long-term response to systemic drugs because the data were focused on treatment initiation. Treatment of pustular psoriasis in pediatrics is challenging. Although acitretin, methotrexate, and cyclosporine seem to control generalized pustular psoriasis within 3 months of therapy initiation, information on long-term follow-up is lacking. Furthermore, physicians may encounter difficulties after discontinuing or tapering medications.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Systemic Medications for Pustular Psoriasis in Pediatrics

Rios

Pope

Lara‐Corrales

2014

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…4 In the present review, eight new studies on the use of retinoids were identified. [27][28][29][30][31][32][33][34] Five studies were excluded because of systemic anti-psoriatic combination therapy 27,[30][31][32][33] and one study because of an unclear treatment regimen. 34 One case report 28 (LOE5) described clearance after 6 weeks of treatment with acitretin 1 mg/kg/day in a 6-weeks-old girl with generalized pustular psoriasis (GPP); safety data were not reported.…”

Section: Retinoidsmentioning

confidence: 99%

Systemic treatments in paediatric psoriasis: a systematic evidence‐based update

Geel

Mul

Jager

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

In 2008, a systematic review revealed that evidence-based data on efficacy and safety of treatments in paediatric psoriasis are scarce and with low level of evidence. In recent years, publications on this topic have increased exponentially. To present a systematic, evidence-based update on the efficacy and safety of systemic treatments in paediatric psoriasis and to provide treatment recommendations, an update of the previous review was performed. PubMed, EMBASE and the Cochrane Controlled Clinical Trial Register were searched between January 2007 and March 2014 for all available literature on efficacy and safety of all systemic treatments in paediatric psoriasis. The levels of evidence were determined on the Oxford Centre for Evidence-based Medicine Levels of Evidence. The newly retrieved evidence was combined with the evidence available in the former review. Fifty-two studies were included: 36 from the former review, plus 16 new articles. New evidence on induction therapy was mainly available on fumaric acid esters (FAEs), which are shown to be effective in a subgroup of patients. Long-term (96 weeks) safety and efficacy data on etanercept were found. Prospective studies are scarce. Most conclusions are formulated on studies with low level of evidence. Of the conventional systemic treatments, methotrexate still has the most evidence albeit in a low number of patients and with a low level of evidence. FAEs seem to be effective in a subgroup of patients, with gastro-intestinal complaints, flushes and temporary shifts in leucocyte counts and liver enzymes being the main side-effects. Etanercept has still accumulated most evidence of the available systematic treatments, with a large efficacy and reassuring safety profile in a 96-week follow-up.

show abstract

“…The dose of acitretin was reduced to 0.4 mg/ kg/day during this period and was stopped after one month, no relapse was seen in the next month (Chao, Cheng, & Chung, 2009). The dose of acitretin was reduced to 0.4 mg/ kg/day during this period and was stopped after one month, no relapse was seen in the next month (Chao, Cheng, & Chung, 2009).…”

Section: Ergin Et Al Reported a Case Of Infantile Pustular Psoriasismentioning

confidence: 99%

“…The patient's skin was normal after 6 weeks and there was no flare in the following 6 months. The dose of acitretin was reduced to 0.4 mg/ kg/day during this period and was stopped after one month, no relapse was seen in the next month (Chao, Cheng, & Chung, 2009).…”

Section: Salleras Et Al Reported a Case Of A 4-year-old Girl With Comentioning

confidence: 99%

Management of pediatric psoriasis with acitretin: A review

Subedi

Chen

et al. 2017

Dermatologic Therapy

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease of the skin which can occur at any age-group. Psoriasis in childhood is not uncommon and has genetic susceptibility but usually, an environmental trigger such as infection is thought to initiate the disease process. Pediatric psoriasis has profound effects on both physical and psychosocial health of the patient. Treatment of mild psoriasis can be done with topical therapies but those which do not respond to topical therapies can be treated with phototherapy and systemic therapies. The use of systemic therapies in childhood is mainly based on the published data, case series, expert opinion and the experience as there is the lack of controlled trials in the age group. Based on the experience retinoids are probably the second line drugs for the treatment of pediatric psoriasis which do not respond to topical therapies and phototherapy. Using acitretin in a low dose and with proper physical examinations and laboratory investigations will reduce the hazard of potential serious adverse events. This article gives the review of the use of acitretin in pediatric psoriasis.

show abstract

Generalized Pustular Psoriasis in a 6‐week‐old Infant

Cited by 31 publications

References 5 publications

A Systematic Review of Systemic Medications for Pustular Psoriasis in Pediatrics

A Systematic Review of Systemic Medications for Pustular Psoriasis in Pediatrics

Systemic treatments in paediatric psoriasis: a systematic evidence‐based update

Management of pediatric psoriasis with acitretin: A review

Contact Info

Product

Resources

About